WealthTrust Asset Management LLC Purchases New Holdings in Bristol Myers Squibb Company (NYSE:BMY)

WealthTrust Asset Management LLC bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,649 shares of the biopharmaceutical company's stock, valued at approximately $893,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Xponance Inc. grew its stake in shares of Bristol Myers Squibb by 9.0% in the first quarter. Xponance Inc. now owns 363,979 shares of the biopharmaceutical company's stock valued at $22,199,000 after buying an additional 30,040 shares in the last quarter. WESPAC Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at $949,000. Sage Rhino Capital LLC grew its stake in shares of Bristol Myers Squibb by 5.8% in the first quarter. Sage Rhino Capital LLC now owns 4,524 shares of the biopharmaceutical company's stock valued at $276,000 after buying an additional 246 shares in the last quarter. Fidelis Capital Partners LLC grew its stake in shares of Bristol Myers Squibb by 78.3% in the first quarter. Fidelis Capital Partners LLC now owns 22,993 shares of the biopharmaceutical company's stock valued at $1,402,000 after buying an additional 10,099 shares in the last quarter. Finally, Genus Capital Management Inc. grew its stake in shares of Bristol Myers Squibb by 169.3% in the first quarter. Genus Capital Management Inc. now owns 19,990 shares of the biopharmaceutical company's stock valued at $1,219,000 after buying an additional 48,820 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Piper Sandler started coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Wall Street Zen cut Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. UBS Group lowered their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. Finally, Morgan Stanley lowered their target price on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating for the company in a research note on Thursday. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $57.69.

Insider Transactions at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president directly owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.09% of the stock is owned by company insiders.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock traded down $1.61 on Friday, hitting $46.91. The stock had a trading volume of 13,670,701 shares, compared to its average volume of 12,845,758. Bristol Myers Squibb Company has a 52-week low of $39.93 and a 52-week high of $63.33. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. The stock has a market cap of $95.47 billion, a price-to-earnings ratio of 17.57, a P/E/G ratio of 2.43 and a beta of 0.36. The company's 50 day moving average price is $47.51 and its 200 day moving average price is $53.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the previous year, the business earned ($4.40) EPS. The business's quarterly revenue was down 5.6% on a year-over-year basis. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 92.88%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.